Navigation Links
Gene variant ID could lead to better fatty liver disease diagnosis
Date:4/23/2013

More patients could be diagnosed earlier with non-alcoholic fatty liver disease (NAFLD) after a cohort study presented at the International Liver CongressTM 2013 identified variants within four genes significantly associated with the histological features of the disease.

NAFLD is caused by a fatty liver; when fat is deposited in the liver not due to the use of alcohol. The spectrum of the disease is broad, ranging from simple fat deposition without inflammation (steatosis), to liver inflammation (steatohepatitis), eventually accompanied by a variable degree of fibrosis. In case of severe fibrosis progession, cirrhosis may develop. NAFLD is currently regarded as a major cause of cirrhosis of the liver of unknown cause.

As NAFLD patients are typically asymptomatic, even in the presence of more severe liver lesions, patient diagnostic techniques to identify at-risk individuals would be very helpful to improve the management of the disease.

Previous genome-wide association studies (GWAS) have provided important insights into modifier genes which influence the pathology of steatosis. Using data drawn from a large GWAS of 1125, European and North American Caucasian patients with NAFLD, this study applied a candidate-gene approach to re-examine the broader validity of these associations.

Variants within four genes significantly associated with the histological features of NAFLD were identified including steatosis (PNPLA3 rs738409, GCKR rs780094, PPP1R3B rs11777327, TRIB1 rs2385114); steatohepatitis (PNPLA3, GCKR, TRIB1); and fibrosis (PNPLA3, GCKR, TRIB1).

This study has further established the overwhelming significance of the chromosome 22 PNPLA3 locus to all aspects of NAFLD and has, for the first time, demonstrated that some genetic variations previously associated with steatosis or mild biochemical abnormalities may in fact have broader pathological significance influencing inflammatory disease and progression to fibrosis in NAFLD. A screening of these genes could be used in future genetic diagnostics to identify patient prone to development of NAFLD, if these results will be confirmed in prospective studies.


'/>"/>

Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-079-001-68904
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. Common gene variants explain 42 percent of antidepressant response
2. An international study identifies new DNA variants that increase the risk for cancer
3. eVariant Welcomes Advocate Health Care
4. Gene variants found to affect human lifespan
5. Researchers Link 25 New Gene Variants to Autism
6. Carriers of gene variant appear less likely to develop heart disease
7. More Gene Variants Linked to Heart Trouble
8. Bigger human genome pool uncovers rarer variants
9. New gene variants raise risk of neuroblastoma, influence tumor progression
10. Mayo, UCSF team discovers genomic variant that increases risk of brain tumors
11. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology: